Please use this identifier to cite or link to this item:
Title: Transcranial magnetic stimulation intervention in Alzheimer's disease: A research proposal for a randomized controlled trial NCT03121066 NCT
Author: Muñoz Marrón, Elena  
Viejo Sobera, Raquel  
Quintana, María
Redolar Ripoll, Diego
Rodríguez, Daniel
Garolera Freixa, Maite
Others: Consorci Sanitari de Terrassa
Universitat Oberta de Catalunya. Estudis de Ciències de la Salut
Keywords: Alzheimer's disease
Theta burst stimulation
parietal cortex
non-invasive brain stimulation
dorsolateral prefrontal cortex
functional connectivity
Issue Date: 5-Sep-2018
Publisher: BMC Research Notes
Citation: Muñoz Marrón, E., Viejo-Sobera, R., Quintana, M., Redolar Ripoll, D., Rodríguez, D. & Garolera, M. (2018). Transcranial magnetic stimulation intervention in Alzheimer's disease: A research proposal for a randomized controlled trial NCT03121066 NCT. BMC Research Notes, 11(1), 1-8. doi: 10.1186/s13104-018-3757-z
Also see:
Abstract: Alzheimer's disease is a major health problem in our society. To date, pharmacological treatments have obtained poor results and there is a growing interest in finding non-pharmacological interventions for this disease. Transcranial magnetic stimulation (TMS) is a non-invasive technique that is able to induce changes in brain activity and long-term modifications in impaired neural networks, becoming a promising clinical intervention. Our goal is to study the benefit of individualized TMS targeting based on the patient's functional connectivity (personalized targeting), and short duration TMS protocol, instead of current non-individualized and longer session approaches. A double blind randomized controlled trial will be conducted to assess the effects of TMS treatment immediately, 1 month, 3 months and 6 months after the end of the intervention. Fifty-four patients with a diagnosis of Alzheimer's disease will be randomly allocated into experimental (active TMS), sham control, or conventional intervention control group. We will quantify changes in cognitive, functional, and emotional deficits in Alzheimer patients, as well as the functional connectivity changes induced by the TMS treatment. Results, we expect to demonstrate that personalized TMS intervention has a measurable positive impact in cognition, emotion, daily living activities and brain connectivity, thus representing a potential treatment for Alzheimer's disease. Trial registration The trial has been prospectively registered at, identifier NCT03121066.
Language: English
ISSN: 1756-0500MIAR
Appears in Collections:Articles

Files in This Item:
File Description SizeFormat 
magneticstimulation.pdf1.06 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons